CD274 and esophageal adenocarcinoma: For patients with HER2-negative G/GEJa, pembrolizumab and nivolumab (another PD-1 inhibitor) are approved for 1L treatment of adults with HER2-negative advanced or metastatic G/GEJ or esophageal adenocarcinoma whose tumors express PD-L1 [17,18,20].